2024
Racial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2009
Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.Peer-Reviewed Original ResearchConceptsWaldenstrom's macroglobulinemiaLymphoplasmacytic cellsClonal lymphoplasmacytic cellsHigh-dose chemotherapyBone marrow infiltrationInternational Staging SystemStem cell transplantationB-cell disordersComplete remissionFrontline therapyObjective responseMarrow infiltrationCell transplantationStaging systemTherapeutic armamentariumMonoclonal gammopathyNovel agentsMacroglobulinemiaTherapyProteasome inhibitorsDisease biologyNucleoside analoguesPromising activityRecent studiesRecent advances